

Ref. No.: LASA/SE/18-19/030

Tuesday August 21, 2018

To, Corporate Services Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. BSE CODE –540702	To, Corporate Services Department National Stock Exchange of India Limited "Exchange Plaza", Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. NSE CODE: LASA
--	--

Dear Sir/Madam,

Sub: Newspaper Advertisement

Pursuant to Regulation 47 of the Securities and Exchange Board of the India (Listing Obligation and Disclosure Requirement) Regulation, 2015, please find enclosed herewith copy of newspaper advertisements.

Please take the same on your records.

Thanking You,

Yours Sincerely,
For LASA SUPERGENERICS LIMITED

Nidhi
21/8/2018
Nidhi Kulshreshtha
Company Secretary and Compliance Officer
Encl: as above.





LASA SUPERGENERICS LIMITED

CORPORATE OFFICE : B/207, City Point, Near Kohirnor Hotel,
 J B Nagar (Chakala), Metro Station, Andheri (E), Mumbai - 400059, Maharashtra, India,
 Tel: 022-4970 1092, Email: mail@lasalabs.com, Website: lasalabs.com
 FACTORY & REGD. OFFICE : Plot No. C-105, MIDC, Mahad, Dist. Raigad,
 Maharashtra India. Tel.: +91-2145-232101 / 232202
 CIN : L24233MH2016PLC274202

**Statement of Unaudited Financial Results for the Quarter ended
 30th June, 2018**

(Rs. In Lakhs)

Particulars	Quarter ended		Year ended	
	30.06.2018 (Unaudited)	31.03.2018 (Unaudited) Refer Note No. 3	30.06.2017 (Unaudited)	31.03.2018 (Audited)
1. INCOME				
a. Revenue from Operations	3,292.06	5,931.18	6,101.02	24,583.88
b. Other Income	101.88	63.55	129.87	348.66
Total Income	3,393.94	5,994.73	6,230.89	24,932.54
2. Expenses				
a. Cost of Materials consumed	1,701.13	5,404.09	3,155.74	17,205.86
b. Cost of Traded Goods	599.79	-	-	-
c. Change in Inventories of Finished Goods, Work-in-Progress and Stock in trade	(184.29)	(281.86)	535.34	(55.34)
d. Excise Duty on Sales (Refer Note No.2)	-	-	231.29	231.29
e. Employee benefits expenses	268.21	272.86	237.48	1,027.09
f. Finance costs (Refer Note No.4)	360.96	261.56	253.38	1,134.35
g. Depreciation & amortizations expenses	480.13	525.32	241.52	1,816.66
h. Other Expenses	385.65	593.11	410.44	2,049.30
Total Expenses (a to g)	3,611.58	6,775.08	5,065.19	23,409.21
Exceptional Items	-	-	-	-
3. Profit / (Loss) before tax (1-2)	(217.64)	(780.36)	1,165.70	1,523.33
4. Tax expense				
Current Tax	-	(193.43)	242.32	316.33
Deferred Tax	79.97	62.11	218.12	(26.99)
Short / Excess Income tax provision for earlier years	-	(1.73)	1.73	-
5. Net Profit / (Loss) after tax (3-4)	(297.61)	(647.31)	703.53	1,233.99
6. Other Comprehensive Income Items that will not be reclassified into Profit or Loss				
- Remeasurement of Defined Benefit Plans (Net of tax)	-	(0.10)	(0.75)	(1.42)
7. Total Comprehensive Income for the year (after tax) (5+6)	(297.61)	(647.41)	702.79	1,232.58
8. Paid-up Equity Share Capital (Face Value of Re. 10/- each)	2,286.44	2,286.44	2,286.44	2,286.44
9. Other Equity excluding Revaluation reserve as per Balance Sheet	9,150.03	9,447.64	6,189.41	9,447.64
10. Earnings per Equity Share (of Rs. 10/- each)				
(a) Basic	(1.30)	(2.83)	3.08	5.40
(b) Diluted	(1.30)	(2.83)	3.08	5.40

See accompanying Notes to the Financial Results

Notes :

- The Above Financial Results were reviewed by the audit committee of the board on 13th August, 2018 and approved by the Board of Directors of the company at their meeting held on same date. The Statutory auditor have expressed on unmodified opinion. The review report has been filled with stock exchange and is available on the company's website. The Financial results have been prepared in accordance with Ind As notified under the companies (Accounting Standards) Rule 2015.
- Post implementation of Goods and Services Tax ("GST") in India with effect from 1st July, 2017, revenue are disclosed net of GST. Revenues for the earlier periods included excise duty which is now subsumed in the GST effective from 1st July 2017. Accordingly, revenues for the quarter ended 30th June, 2018 are not comparable with previous comparative quarter ended 30th June, 2017.
- The figures of the fourth quarter ended 31st March, 2018 are the balancing figures between audited figures in respect of the full financial year and published year to date figures up to the quarter ended of the relevant financial year. Also the figures upto the quarter ended were only reviewed and not subjected to audit.
- Finance cost includes Rs. 116.50 Lakhs being loss on account of foreign exchange fluctuations and Rs. 4.77 Lakhs being gain on account of foreign exchange fluctuations during the quarter ended 30th June, 2018 and 30th June, 2017 respectively.
- The Company has only one reportable segment i.e. Active Pharma Ingredients (API)
- The pricing pressure of most of the raw materials in reporting quarters continued to increase and reached at a such extent that in order to utilise full capacity we may have taken biggest hit either on margins or in business front. Margins would have negative if the case be of full capacity utilisation, however to maintain reasonable balance on margins we decided to execute business upto extent which shall give atleast positive level of gross margins. Also one of the majors reason for declined top lines is drastic drop in universal demand for one of our top product. We are putting all our efforts to improve profitability in upcoming quarters.
- Figures of previous period have been re-grouped / reclassified wherever necessary, to confirm to this period's classification.

By order of the Board of Directors
 For Lasa Supergenerics Limited
 Sd/-

Omkar Herlekar

Chairman & Managing Director
 (DIN No. 01587154)

Place : Mumbai

Date : 13th August, 2018



LASA SUPERGENERIC LIMITED

CORPORATE OFFICE : B/207, City Point, Near Kohimnor Hotel,
 JB Nagar (Chakala), Metro Station, Andheri (E), Mumbai - 400059, Maharashtra, India.
 Tel: 022-4970 1092, Email: mail@lasalabs.com, Website: lasalabs.com
 FACTORY & REGD. OFFICE : Plot No. C-105, MIDC, Mahad, Dist. Raigad,
 Maharashtra India. Tel.: +91-2145-232101 / 232202
 CIN : L24233MH2016PLC274202

Statement of Unaudited Financial Results for the Quarter ended 30th June, 2018

(Rs. In Lakhs)

Particulars	Quarter ended		Year ended	
	30.06.2018 (Unaudited)	31.03.2018 (Unaudited) Refer Note No. 3	30.06.2017 (Unaudited)	31.03.2018 (Audited)
1. INCOME				
a. Revenue from Operations	3,292.06	5,931.18	6,101.02	24,583.88
b. Other Income	101.88	63.55	129.87	348.66
Total Income	3,393.94	5,994.73	6,230.89	24,932.54
2. Expenses				
a. Cost of Materials consumed	1,701.13	5,404.09	3,155.74	17,205.86
b. Cost of Traded Goods	599.79	-	-	-
c. Change in Inventories of Finished Goods, Work-in-Progress and Stock in trade	(184.29)	(281.86)	535.34	(55.34)
d. Excise Duty on Sales (Refer Note No.2)	-	-	231.29	231.29
e. Employee benefits expenses	268.21	272.86	237.48	1,027.09
f. Finance costs (Refer Note No.4)	360.96	261.56	253.38	1,134.35
g. Depreciation & amortizations expenses	480.13	525.32	241.52	1,816.66
h. Other Expenses	385.65	593.11	410.44	2,049.30
Total Expenses (a to g)	3,611.58	6,775.08	5,065.19	23,409.21
Exceptional Items				
3. Profit / (Loss) before tax (1-2)	(217.64)	(780.36)	1,165.70	1,523.33
4. Tax expense				
Current Tax	-	(193.43)	242.32	316.33
Deferred Tax	79.97	62.11	218.12	(26.99)
Short/ Excess income tax provision for earlier years	-	(1.73)	1.73	-
Net Profit / (Loss) after tax (3-4)	(297.61)	(647.31)	703.53	1,233.99
5. Other Comprehensive Income				
Items that will not be reclassified into Profit or Loss				
- Remeasurement of Defined Benefit Plans (Net of tax)	-	(0.10)	(0.75)	(1.42)
7. Total Comprehensive Income for the year (after tax) (5+6)	(297.61)	(647.41)	702.79	1,232.58
8. Paid-up Equity Share Capital (Face Value of Re. 10/- each)	2,286.44	2,286.44	2,286.44	2,286.44
9. Other Equity excluding Revaluation reserve as per Balance Sheet	9,150.03	9,447.64	6,189.41	9,447.64
10. Earnings per Equity Share (of Rs. 10/- each)				
(a) Basic	(1.30)	(2.83)	3.08	5.40
(b) Diluted	(1.30)	(2.83)	3.08	5.40

See accompanying Notes to the Financial Results

Notes :

- The Above Financial Results were reviewed by the audit committee of the board on 13th August, 2018 and approved by the Board of Directors of the company at their meeting held on same date. The Statutory auditor have expressed on unmodified opinion. The review report has been filled with stock exchange and is available on the company's website. The Financial results have been prepared in accordance with Ind As notified under the companies (Accounting Standards) Rule 2015.
- Post implementation of Goods and Services Tax ("GST") in India with effect from 1st July, 2017, revenue are disclosed net of GST. Revenues for the earlier periods included excise duty which is now subsumed in the GST effective from 1st July 2017. Accordingly, revenues for the quarter ended 30th June, 2018 are not comparable with previous comparative quarter ended 30th June, 2017.
- The figures of the fourth quarter ended 31st March, 2018 are the balancing figures between audited figures in respect of the full financial year and published year to date figures up to the quarter ended of the relevant financial year. Also the figures upto the quarter ended were only reviewed and not subjected to audit.
- Finance cost includes Rs. 116.50 Lakhs being loss on account of foreign exchange fluctuations and Rs. 4.77 Lakhs being gain on account of foreign exchange fluctuations during the quarter ended 30th June, 2018 and 30th June, 2017 respectively.
- The Company has only one reportable segment i.e. Active Pharma Ingredients (API)
- The pricing pressure of most of the raw materials in reporting quarters continued to increase and reached at a such extent that in order to utilise full capacity we may have taken biggest hit either on margins or in business front. Margins would have negative if the case be of full capacity utilisation, however to maintain reasonable balance on margins we decided to execute business upto extent which shall give atleast positive level of gross margins. Also one of the majors reason for declined top lines is drastic drop in universal demand for one of our top product. We are putting all our efforts to improve profitability in upcoming quarters.
- Figures of previous period have been re-grouped / reclassified wherever necessary, to confirm to this period's classification.

By order of the Board of Directors
 For Lasa Supergenerics Limited
 Sd/-

Omkar Herlekar
 Chairman & Managing Director
 (DIN No. 01587154)

Place : Mumbai

Date : 13th August, 2018

मुंबई लक्षदीप



LASA

LASA SUPERGENERICS LIMITED

Reg Off: C-105, MIDC, Mahad, Dist - Raigad, Mahad - 402309

Corporate Office: B-207, CITIPOINT, Near Kohinoor Hotel, J.B.

Nagar, Andheri (E), Mumbai - 400059, Tel: +91 22 4970 1092

Website: www.lasalabs.com, Email ID: investor@lasalabs.com

CIN: L24233MH2016PLC274202

NOTICE

Pursuant to Regulation 29 read with Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, Notice is hereby given that the Meeting of the Board of Directors of the Company is scheduled to be held on Monday, August 13, 2018 at 11.00 a.m. at the Corporate Office of the Company. Inter-alia, to consider and approve the Unaudited Financial Result of the Company for the Quarter ended June 30, 2018 and/or any other business/matter with the permission/ approval of the Chairman.

The said notice is also available on the website of the Company at www.lasalabs.com and on the website of the Stock exchanges i.e. www.bseindia.com and www.nseindia.com.

For Lasa Supergenerics Limited
Sd/-

NidhiKulshreshtha

Company Secretary

Place: Mumbai

Date : August 2, 2018



LASA SUPERGENERICS LIMITED

Reg Off: C-105, MIDC, Mahad, Dist - Raigad, Mahad - 402309
Corporate Office: B-207, CITIPOINT, Near Kohinoor Hotel, J.B. Nagar, Andheri (E), Mumbai - 400059, Tel: +91 22 4970 1092
Website: www.lasalabs.com, **Email ID:** investor@lasalabs.com
CIN: L24233MH2016PLC274202

NOTICE

Pursuant to Regulation 29 read with Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, Notice is hereby given that the Meeting of the Board of Directors of the Company is scheduled to be held on Monday, August 13, 2018 at 11.00 a.m. at the Corporate Office of the Company. Inter-alia, to consider and approve the Unaudited Financial Result of the Company for the Quarter ended June 30, 2018 and/or any other business/matter with the permission/ approval of the Chairman.

The said notice is also available on the website of the Company at www.lasalabs.com and on the website of the Stock exchanges i.e. www.bseindia.com and www.nseindia.com.

For Lasa Supergenerics Limited
Sd/-
NidhiKulshreshtha
Company Secretary

Place: Mumbai
Date : August 2, 2018